Monday, May 21, 2018
James F. Holland, M.D., a renowned cancer expert who was a major figure in the development of cancer chemotherapy, died on March 22, 2018, at the age of 92. Dr. Holland was among the first group of research physicians recruited to the NIH Clinical Center, serving as a senior surgeon at the National Cancer Institute from 1953 to 1954. In that short year at the NIH, he initiated a clinical trial to compare continuous or intermittent treatment with two chemotherapy agents for acute leukemia in children: methotrexate and 6-mercaptopurine. Dr. Holland moved to Roswell Park Memorial Institute in Buffalo before the trial was completed, but he continued to collaborate. His work ultimately turned an incurable illness into one with an 80% survival rate. In 1972, he and his NIH collaborators shared the Albert Lasker Clinical Medical Research Award for "outstanding contribution to the concept and application of combination therapy in the treatment of acute leukemia in children."
Monday, April 27, 2015
One of the best parts of a new idea is being able to share it! Research is certainly no exception. On Thursday, April 30th, the postbacs of NIH will be sharing their ideas and findings at Postbac Poster Day.
Friday, February 27, 2015
“Then we have ‘prevention is more important than cure.’ That’s the one I like best. That’s my pet peeve…."
Dr. Emil Freireich, NCI, in his 1997 oral history. Dr. Freireich helped develop combined chemotherapy for childhood leukemia.